Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2017 Archives
Dec 21, 2017 --Brings More Than 25 Years of Broad Pharmaceutical Industry Experience, Including Leadership Positions at Cipla, Teva, Dr. Reddy's and Bristol-Myers Squibb-- Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has named Timothy C. Crew as the company's chief executive officer (CEO), effective January 2, 2018. The Board of... More |
Dec 11, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2017 Prescription for Success Healthcare Conference on December 14, 2017 at 3:30 p.m.... More |
Dec 1, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Topical Solution, 4% and 10%, with a proposed trade name of... More |
Nov 29, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive... More |
Nov 9, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies London Healthcare Conference on November 15, 2017 at 12:40 p.m. (GMT). A webcast of the... More |
Nov 6, 2017 Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 first quarter ended September 30, 2017. "In recent weeks, we announced a number of very positive developments... More |
Nov 1, 2017 Lannett Company, Inc. (NYSE: LCI) today responded to the allegations in the amended civil complaint by a number of states' attorneys general pending in the U.S. District Court for the Eastern... More |
Oct 30, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S.... More |
Oct 26, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 first quarter on Monday, November 6, 2017, after the market closes. Lannett management... More |
Oct 2, 2017 --Company Cleared to Market Prescription and OTC Generic Prevacid®-- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lansoprazole... More |
Sep 27, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone and... More |
Sep 26, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dexmethylphenidate... More |
Sep 26, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the United States District Judge for the Eastern District of Pennsylvania dismissed in its entirety a putative class action lawsuit against a... More |
Sep 25, 2017 --CEO Arthur Bedrosian to Step Down Upon Naming of a Successor-- Lannett Company, Inc. (NYSE: LCI) today announced that its board of directors has begun a search for a new chief executive officer (CEO). As part of the unanimously approved search process, the... More |
Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). Bedrosian filed a lawsuit against the... More |
Sep 5, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Esomeprazole... More |
Aug 23, 2017 Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "In the coming year, we expect a solid increase in net... More |
Aug 8, 2017 --Company to Report Full Financial Results and Host Conference Call on August 23-- Lannett Company, Inc. (NYSE: LCI) today reported preliminary financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "While our industry is currently facing... More |
Aug 1, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 37th Annual Growth Conference on August 9, 2017 at 4 p.m. (ET) at the InterContinental Hotel in More |
Jul 17, 2017 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general counsel. "I am very pleased to welcome Sam to the Lannett... More |
Jul 14, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine... More |
Jun 26, 2017 --New Dosage Strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Represent Lion's Share of the Market and Complement Previously Approved Dosage Strengths-- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone... More |
Jun 22, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone... More |
Jun 20, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. The addition of LePore will increase the... More |
Jun 19, 2017 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Niacin... More |
| 1-25 26-42 |